Dengue cure: S'pore researchers move to next phase
SingHealth and Duke-NUS in exclusive licensing deal with US firm 60° Pharmaceuticals
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
[SINGAPORE] Even as the world's first dengue vaccine is set to hit Singapore shores next year, reseachers here are one step closer to finding the first antiviral drug that treats the illness.
Researchers from the Singapore General Hospital and Duke-NUS Graduate Medical School completed a study called CELADEN last year that found Celgosivir, a medicine derived from the seeds of the Moreton Bay Chestnut trees, to be safe for dengue patients.
The S$1.6 million clinical trial of the drug was conducted from July 2012 to March 2013 on 50 dengue patients.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts
